FLT3 and acute myeloid leukemia: FLT3 inhibitors have been an archetypal example of a successful molecular-targeting strategy for AML with FLT3 mutations, with the clinical benefit of their front-line use in combination with standard chemotherapy being demonstrated in large-scale clinical trials.